Progenics Pharmaceuticals news from FierceBiotech
News
Progenics, Wyeth drug fails late-stage trial
There's more bad news for Wyeth and Progenics Pharmaceuticals for their late-stage drug Relistor. Researchers say the drug failed to hit a primary endpoint in restoring gastrointestinal function Read more...
FDA approves Wyeth, Progenics drug
There's a big sigh of relief coming from Wyeth and Progenics today as the FDA approved Relistor, a subcutaneous injection for opioid-induced constipation in patients with advanced illness who are Read more...
ALSO NOTED: Dr. Reddy's buys small molecules biz; Labopharm appeals FDA decision; Avant touts typhoid fever data; and much more
> Dr. Reddy's has struck a deal to buy a portion of Dowharma's small molecules business in the UK. Read more...
Four promising companies to watch
Based on strong product pipelines, positive clinical data and impressive partnerships with big drug companies, The Motley Fool profiles four small biopharm companies that could emerge as Read more...
Paid Research Reports
- Leading Drug Delivery Companies and Technologies: Competitive landscape, company profiles and technological developments
- Drug Repositioning Strategies - Serendipity by design
- eHealthInsight Series: Online Patient Recruitment Strategies - Optimizing the clinical trial process
- Pricing & Reimbursement - Seven Major Markets Update
- Innovative Clinical Trial Design and Management: Trends, success stories and impact upon R&D budgets